Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mechanisms Underlying Asthma Exacerbations Prevented and Persistent With Immune-Based Therapy: A Systems Approach Phase 2 (ICAC-30)

Next Previous
X
Search
Trial Profile

Mechanisms Underlying Asthma Exacerbations Prevented and Persistent With Immune-Based Therapy: A Systems Approach Phase 2 (ICAC-30)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mepolizumab (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms MUPPITS-2

    • Most Recent Events

    • 22 May 2024 Results (n=290 in subgroups) assessing the efficacy of mepolizumab in urban children with exacerbation-prone asthma and greater than or equal to 150 blood eosinophils /microliter were presented at the 120th International Conference of the American Thoracic Society.
    • 22 May 2024 Results (n=53) of analysis of mechanisms of asthma exacerbations in the context of anti-IL5 treatment, an in-depth analysis of sputum eosinophil marker expression using mass cytometry presented at the 120th International Conference of the American Thoracic Society.
    • 27 Apr 2021 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top